Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Avanos Medical (AVNS) Long-Term Debt Repayments (2019)

Avanos Medical's Long-Term Debt Repayments history spans 4 years, with the latest figure at $200000.0 for Q3 2019.

On a quarterly basis, Long-Term Debt Repayments changed N/A to $200000.0 in Q3 2019 year-over-year; TTM through Dec 2019 was $400000.0, a N/A change, with the full-year FY2023 number at $4.7 million, down 96.29% from a year prior.
Long-Term Debt Repayments hit $200000.0 in Q3 2019 for Avanos Medical, roughly flat from $200000.0 in the prior quarter.
Over the last five years, Long-Term Debt Repayments for AVNS hit a ceiling of $50.0 million in Q2 2015 and a floor of $200000.0 in Q2 2019.